-+ 0.00%
-+ 0.00%
-+ 0.00%

Cerenome Completes Enrollment In Phase 2 ReSPECT-GBM Trial Of REYOBIQ In Recurrent Glioblastoma; Topline Data Expected Mid-2027

Benzinga·10/29/2026 12:24:09
Listen to the news

Previously reported interim Phase 2 data showed a 63% improvement in median overall